-

INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates CF Finance Acquisition Corp. II’s Directors and Officers for Breach of Fiduciary Duties – VIEW, CFII

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether certain directors and officers of CF Finance Acquisition Corp. II (“CF II”) (NASDAQ: CFII); n/k/a View, Inc. (“View”) (NASDAQ: VIEW) breached their fiduciary duties to CF II’s shareholders. If you were a CF II shareholder, you may contact attorney Joe Pettigrew for additional information toll-free at 844-818-6982 or jpettigrew@scott-scott.com.

On March 5, 2021, CF II shareholders of record as of January 27, 2021, approved a merger between CF II and View. In the months following the merger, negative information repeatedly emerged about View, including:

  • On August 8, 2021, View announced that its Audit Committee retained outside legal counsel and accounting advisors to investigate the company’s prior financial statements.
  • On November 9, 2021, View announced that the Audit Committee’s investigation was “substantially complete” and determined that “previously reported liabilities associated with all warranty-related obligations and the cost of revenue associated with the recognition of those liabilities were materially misstated,” requiring View to restate previously issued financial statements.
  • In connection with these findings, View further disclosed that its Chief Financial Officer had resigned.
  • On May 10, 2022, barely one year after the merger, View disclosed that it “anticipates that it will be disclosing substantial doubt about the Company’s ability to continue as a going concern, as the Company does not currently have adequate financial resources to fund its forecasted operating costs and meet its obligations for at least twelve months from the expected issuance date of its 2021 financial results.”
  • As of January 24, 2023, the stock has declined by over 90% since the merger and currently trades for less than $1.00 per share.

Accordingly, Scott+Scott is investigating whether CF II’s board of directors or executive officers breached their fiduciary duties of loyalty and good faith, and whether CF II’s shareholders suffered damages as a result such misconduct. Among other things, Scott+Scott’s is specifically investigating the truth of disclosures made to stockholders in connection with the merger of CFII and View, including accounting statements provided to stockholders, descriptions of View’s cash positions, and representations regarding View’s ability to become cash flow positive and finance its operations following the merger.

What You Can Do

If you were a CF II shareholder, you may have legal claims against CF II’s directors and officers. If you wish to discuss Scott+Scott’s investigation, or have questions about this notice or your legal rights, please contact attorney Joe Pettigrew toll-free at 844-818-6982 or jpettigrew@scott-scott.com.

About Scott+Scott

Scott+Scott has significant experience in prosecuting major securities, antitrust, and consumer rights actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Amsterdam, Connecticut, California, and Ohio.

Attorney Advertising

Contacts

Joe Pettigrew
Scott+Scott Attorneys at Law LLP
600 W. Broadway, Suite 3300, San Diego, CA 92101
(844) 818-6982
jpettigrew@scott-scott.com

Scott+Scott Attorneys at Law LLP

NASDAQ:CFII

Release Versions

Contacts

Joe Pettigrew
Scott+Scott Attorneys at Law LLP
600 W. Broadway, Suite 3300, San Diego, CA 92101
(844) 818-6982
jpettigrew@scott-scott.com

More News From Scott+Scott Attorneys at Law LLP

Scott+Scott Attorneys at Law LLP Reminds Investors of Its Investigation Into Corcept Therapeutics Incorporated (NASDAQ: CORT)

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a shareholder and consumer rights litigation firm, is investigating whether Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT) or certain of its officers and directors issued misleading and false statements and/or failed to disclose information material to investors in violation of federal securities laws. CLICK HERE TO RECEIVE ADDITIONAL INFORMATION ABOUT THIS POTENTIAL CLASS ACTION Corcept...

Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Charming Medical Limited (NASDAQ: MCTA)

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, today announced that it has filed a class action lawsuit against Defendants Charming Medical, Limited; Kit Wong; Ching Man Cheung; Josephine Yan Yeung; Leut Ming Gung; Shu Tai Victor Yu; Cathay Securities Inc.; WWC, P.C.; And Cogency Global, Inc. (collectively, the “Defendants”). The action, which was filed in the U.S. District Court for the Southern Dist...

Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Charming Medical Limited (NASDAQ: MCTA)

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, today announced that it has filed a class action lawsuit against Defendants Charming Medical, Limited; Kit Wong; Ching Man Cheung; Josephine Yan Yeung; Leut Ming Gung; Shu Tai Victor Yu; Cathay Securities Inc.; WWC, P.C.; And Cogency Global, Inc. (collectively, the “Defendants”). The action, which was filed in the U.S. District Court for the Southern Dist...
Back to Newsroom